'Safe Supply' Co. Secures Legal Flow of Coca Products

  ()
This is a milestone for the venture capital firm investing in efforts that address the toxic drug crisis in Canada and the U.S. Learn more about the company and the latest wave of drug reform.

Alt-Pharma VC adds 7% Stake in Testing Strip Firm

  ()
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio.

Wellness Co. Preparing for US Legislation

Research Report
  ()
Wellness company Canopy Growth Corp. is taking steps forward while it waits for the U.S. to make legislative changes, according to a Roth MKM research note.

Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says

Contributed Opinion
  ()
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly.

Drug Reformer Subsidiary Inspected for Dealer License

  ()
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances.

Leadership Cuts Won't Slow This Biotech

Research Report
  ()
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.

Pharma Co. Primed for Future Business

Research Report
  ()
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development.

Healthcare Co. Exceeds Expectations in Performance

Research Report
  ()
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.

Innovator in Drug Policy Now Listed on the OTCQBA Venture Market

  ()
Safe Supply Streaming Co. Ltd. Announced that it is expanding availability for potential investors. Read on to see why this stock might represent an opportunity as drug policy changes.
Tags:  Psychedelics

Pharma Co. Invests in Clinical Psychedelics

  ()
ATAI Life Sciences N.V. has announced that it is investing in psychedelic treatments for Major Depressive Disorder and Alcohol Use Disorder. Read on to see why one analyst likes this company's stock.
Tags:  Psychedelics

Money Manager: The Year of Small Caps?

  ()
The president and chief executive officer of Toronto-based AlphaNorth Asset Management says his positive outlook on 2024 has not changed. In fact, it could be a great year for small caps.

Telehealth Co. Adding Thousands to Large Contract

  ()
Reliq Health Technologies Inc. has signed a contract expansion with a large U.S. health plan, possibly adding as many as 50,000 new patients to its iUGO telehealth platform.

Biotech Co.'s Sales Could Grow To US$310 Million in 2028

Research Report
  ()
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.

Big Pharma's Looming Patents May Benefit One Biotech

  ()
Pharma stocks took big hits in recent years as many of its largest companies saw a looming "patent cliff" that could dry out profits from their big cash-cow drugs. This may be good for smaller pharma companies like one stock, which was one of Chen Lin's top picks for 2024.

2024: Chen Leads With Biotech After Picking 2023's Top Stock

  ()
Asset manager Chen Lin was very happy with his picks from 2023, including one that ended up soaring 1,900%. See what the asset manager has lined up for the new year.

Boston Biotech Could Have Blockbuster Sales

Research Report
  ()
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Market Correction and One Cash Rich Biotech

Contributed Opinion
  ()
In late December, Ron Struthers pointed out that the S&P 500 made a double top and showed numerous over-bought conditions, so a correction is expected. He also shared one biotech that has been whacked down way below its cash value.

California-Based Pharma Co.'s Progress Offers Upside

Research Report
  ()
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.

Pharma Co. Gets First US Patent for Repurposed Drug

  ()
Clinical-stage pharmaceuticals firm Algernon Pharmaceuticals Inc. has been issued a U.S. patent for the treatment of three related diseases with its investigational drug repirinast.

Co.'s Breast Cancer Therapy Shows Encouraging Activity

Research Report
  ()
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.

Biotech Secures Additional Funding, Extending Cash Runway

Research Report
  ()
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.